Enzyme replacement therapy for MPS IVA using recombinant human GALNS, or elosulfase alfa [13], was approved by FDA and EMA in 2014, for children and adults with Morquio A syndrome [14]. This evidence concerns the gene GALNS and mucopolysaccharidosis type 4A.